Lakefront Biotherapeutics

Galapagos is now Lakefront Biotherapeutics.

[Lakefront Biotherapeutics @LakefrontBio]

Press Release | Galapagos Reports First Quarter 2026 Financial Results and Provides Business Update

Galapagos will host a conference call and webcast presentation May 7, 2026, at 14:00 CET / 8:00 am ET.

Read more in our press release: https://t.co/8aQVcSQ1NO

[Lakefront Biotherapeutics @LakefrontBio]

We're pleased to share that today our shareholders approved our proposal to change our name to Lakefront Biotherapeutics, effective May 8th.

Read more: https://t.co/ltSHPpzmKz

[Lakefront Biotherapeutics @LakefrontBio]

Press Release | Galapagos and Gilead Enter into Binding Agreement to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases.

Read more in our press release: https://t.co/7moltlG5S4

[Lakefront Biotherapeutics @LakefrontBio]

Press Release | Galapagos Publishes 2025 Annual Report and Announces Annual and Extraordinary Shareholders’ Meetings

Read more: https://t.co/JLUdIqejt1

[Lakefront Biotherapeutics @LakefrontBio]

Press release | Galapagos Appoints Tania Philipp as Chief Human Resources Officer.

A seasoned life sciences executive, Ms. Philipp joins Galapagos with a strong track record in change management.

Read more:
https://t.co/c17Ed266sR

[Lakefront Biotherapeutics @LakefrontBio]

📢 Watch the replay of our full year 2025 earnings conference call for investors and analysts.

For details, visit our Webcasts section:

https://t.co/WPjVEyZY8z

[Lakefront Biotherapeutics @LakefrontBio]

Press release | Galapagos Reports Full Year 2025 Results and Provides Fourth Quarter Business Update

Read more: https://t.co/lWhv3e4I2E

[Lakefront Biotherapeutics @LakefrontBio]

Press release | Galapagos Welcomes Dr. Paulo Fontoura to its Board of Directors.

Dr. Fontoura brings extensive global leadership, clinical development, and operational experience to the Board.

Read more: https://t.co/iNk9up9gwf

[Lakefront Biotherapeutics @LakefrontBio]

📢 Galapagos to Host Conference Call to Discuss Full Year 2025 Financial Results and Provide Fourth Quarter Business Update on February 23, 2026.

For details, visit our Webcasts section:
https://t.co/WPjVEz0vY7

[Lakefront Biotherapeutics @LakefrontBio]

As 2025 comes to a close, we want to thank our colleagues, our partners, the scientific communities and the patients who participate in our clinical studies for the collaboration, dedication, and shared purpose that define our work.

Happy holidays!

[Lakefront Biotherapeutics @LakefrontBio]

Press Release | Galapagos Announces Topline Results from Two Phase 3-Enabling Studies with Selective TYK2 Inhibitor in Dermatomyositis and Systemic Lupus Erythematosus.

Read more: https://t.co/8mDdlhYhJJ

[Lakefront Biotherapeutics @LakefrontBio]

We are pleased to announce the formation of Galapagos’ Cross-Disciplinary Strategic Advisory Board.

Our new advisors — Dr. Scott Brun, Dr. Rob Lenz, Elaine Sorg, and Dr. Nancy Valente — bring deep experience across scientific innovation, development, and commercialization.

[Lakefront Biotherapeutics @LakefrontBio]

📢 Watch the replay of our third quarter 2025 earnings conference call for investors and analysts.

For details, visit our Webcasts section:
https://t.co/WPjVEyZY8z

[Lakefront Biotherapeutics @LakefrontBio]

Press release | Galapagos Reports First Nine Months of 2025 Financial Results and Provides Business Update

Read more: https://t.co/m8iYE9b2mJ

[Lakefront Biotherapeutics @LakefrontBio]

Press release | Galapagos to Present New Data from Cell Therapy Program at #ASH2025.

Read more: https://t.co/cbbiOTGwp4

[Lakefront Biotherapeutics @LakefrontBio]

Press Release ǀ Galapagos Welcomes Dr. Neil Johnston and Devang Bhuva to its Board of Directors.

New Directors bring strong financial leadership, capital allocation, and business development expertise to the Board.

Read more: https://t.co/52ldlBiqL2

[Lakefront Biotherapeutics @LakefrontBio]

📢 Galapagos to Host Conference Call to Discuss First Nine Months of 2025 Financial Results and Business Update on November 6, 2025.

For details, visit our Webcasts section:
https://t.co/WPjVEz0vY7

[Lakefront Biotherapeutics @LakefrontBio]

Press Release ǀ Galapagos to present new data on its TYK2 inhibitor at #ACR25.

At clinically relevant exposures, the drug candidate showed selective inhibition of TYK2-mediated signaling, while sparing the IL-10 anti-inflammatory pathway.

Read more: https://t.co/zlcspos7BN

[Lakefront Biotherapeutics @LakefrontBio]

Press release | Galapagos Announces Intention to Wind Down Cell Therapy Business as Part of the Company’s Ongoing Transformation.

Read the full press release: https://t.co/fpH1UDZIYn

[Lakefront Biotherapeutics @LakefrontBio]

We’re pleased to welcome Fred Blakeslee as EVP & General Counsel, effective October 16. Having most recently served as VP, Transactions, Legal at AbbVie, Fred brings extensive legal and transactional expertise to the Galapagos executive team.

Read more: https://t.co/2F9DIFP1x5